Perioperative medicine & outcomes
Comparing the efficacy and safety of thromboprophylaxis with enoxaparin versus normal saline after liver transplantation: randomized clinical trial
Authors' conclusion
Use of prophylactic anticoagulation with enoxaparin is associated with a significantly higher incidence of major bleeding in patients undergoing deceased-donor liver transplantation, rather than a lower likelihood of venous thrombosis.
Study context
- Population
- Patients undergoing deceased-donor liver transplantationrecruited
- Participants
- 462 patients
- Comparison
- Enoxaparin vs normal saline after liver transplantation
- Primary endpoint
- Incidence of venous thrombosis (portal vein thrombosis and DVT); primary safety outcome major bleeding
- Follow-up
- 90 days
Methodological detailsdual-centre
- Dual-centre
Primary result
As reported in the abstract
Venous thrombosis
Venous thrombosis, all patients
89
19.3%
Further findings
DVT in hepatocellular carcinoma patients (subgroup)
- Anticoagulation associated with lower risk of DVT in hepatocellular carcinoma patients
- HR 0.44 (95% c.i. 0.23 to 0.86), P = 0.016
- Without a significantly higher risk of major bleeding in hepatocellular carcinoma patients
Venous thrombosis, portal vein thrombosis, DVT
- No significant differences between the two groups
- Intention-to-treat
Safety
Major bleeding (primary safety outcome) · within 90 days after transplantation
- Markedly elevated incidence of major bleeding in the anticoagulant group vs the other group
- 35.5% versus 25.5%, P = 0.020
- Major bleeding, all patients
- 141 (30.5%)
- Intention-to-treat
Original publication
Comparing the efficacy and safety of thromboprophylaxis with enoxaparin versus normal saline after liver transplantation: randomized clinical trial. Br J Surg. Published 24 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →